Outcomes of Chemoimmunotherapy in Metastatic Pancreatic Neuroendocrine Carcinoma: A Single-Center Clinicopathologic Study.
Drew Moss, Catherine A O'Connor, Marc Hilmi...
https://pubmed.ncbi.nlm.nih.gov/42949119/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-11-04
189
Participants Needed
266
Research Sites
N/A
Total Duration
Researchers are studying advanced or metastatic poorly differentiated neuroendocrine carcinomas that originate outside the lung. This trial compares the effects of adding the immunotherapy drug atezolizumab to standard chemotherapy with a platinum drug cisplatin or carboplatin and etoposide versus using standard chemotherapy alone. They also compare giving atezolizumab only during initial treatment versus continuing it afterward. The study aims to understand how these treatments affect cancer progression and survival. Participants are randomly assigned to one of three groups. One group receives induction treatment with atezolizumab plus platinum and etoposide chemotherapy for four 21-day cycles, followed by maintenance atezolizumab for up to 17 more cycles. Another group receives the same induction treatment but then undergoes observation for one year. The third group receives only the platinum and etoposide chemotherapy for four cycles followed by observation for one year. During treatment, atezolizumab and chemotherapy are given intravenously with specific dosing schedules. Throughout the trial, participants undergo CT scans andor MRI to monitor disease status and have regular blood samples collected. After completing treatment, participants are followed for up to five years to assess overall survival and other outcomes like progression-free survival and response rates. The study also evaluates safety and collects tumor and blood samples for future research.
CONDITIONS
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Atezolizumab plus platinum‑etoposide (trial investigational) | Platinum‑etoposide (trial comparator) | Platinum‑etoposide (external standard care) |
|---|---|---|---|
| What it is | Experimental combination of atezolizumab (an anti‑PD‑L1 immunotherapy) with platinum‑etoposide chemotherapy | Standard platinum‑etoposide chemotherapy without immunotherapy | Established first‑line treatment for advanced extrapulmonary poorly differentiated NEC |
| Role in trial | Investigational experimental arm | Active comparator arm receiving chemotherapy only | Current standard‑of‑care benchmark |
| Primary use | Treatment of advanced or metastatic extrapulmonary NEC combining immunotherapy and chemotherapy | Treatment of advanced or metastatic extrapulmonary NEC with chemotherapy alone | Widely used first‑line systemic therapy for this condition |
| How it is given or performed | IV administration of atezolizumab combined with IV platinum (cisplatin or carboplatin) plus IV etoposide | IV platinum (cisplatin or carboplatin) plus IV etoposide | IV platinum plus etoposide chemotherapy |
| Evidence status | Efficacy being evaluated in this Phase II/III trial; not yet established | Established efficacy as first‑line therapy, based on guideline consensus | Strong evidence supports its use as standard first‑line treatment |
| Important limitations | Benefit and safety not yet known in this specific population; trial results pending | Response durations often short and prognosis remains poor despite chemotherapy | Limited duration of response and challenging prognosis persist even with standard care |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 12 weeks
Participants receive intravenous atezolizumab, carboplatin or cisplatin, and etoposide every 21 days for 4 cycles unless disease progresses or toxicity occurs.
4 treatment cycles every 3 weeks
Duration - Up to 51 weeks
Participants either receive maintenance atezolizumab every 21 days for up to 17 cycles or undergo observation for 1 year, depending on their assigned group.
Regular visits during maintenance or observation
Duration - Up to 5 years
After treatment completion, participants are followed for up to 5 years to monitor overall survival and other health outcomes.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Drew Moss, Catherine A O'Connor, Marc Hilmi...
https://pubmed.ncbi.nlm.nih.gov/42949119/National Cancer Institute (NCI)
Lead Sponsor